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Abstract
Background: Oxygen, haemoglobin and cardiac output are integrated components of oxygen transport: each gram of
haemoglobin transports 1.34 mls of oxygen in the blood. Low arterial partial pressure of oxygen (PaO2), and haemoglobin
saturation (SaO2), are the indices used in clinical assessments, and usually result from low inspired oxygen concentrations, or
alveolar/airways disease. Our objective was to examine low blood oxygen/haemoglobin relationships in chronically
compensated states without concurrent hypoxic pulmonary vasoreactivity.
Methodology: 165 consecutive unselected patients with pulmonary arteriovenous malformations were studied, in 98 cases,
pre/post embolisation treatment. 159 (96%) had hereditary haemorrhagic telangiectasia. Arterial oxygen content was
calculated by SaO2 x haemoglobin x 1.34/100.
Principal Findings: There was wide variation in SaO2 on air (78.5–99, median 95)% but due to secondary erythrocytosis and
resultant polycythaemia, SaO2 explained only 0.1% of the variance in arterial oxygen content per unit blood volume.
Secondary erythrocytosis was achievable with low iron stores, but only if serum iron was high-normal: Low serum iron levels
were associated with reduced haemoglobin per erythrocyte, and overall arterial oxygen content was lower in iron deficient
patients (median 16.0 [IQR 14.9, 17.4]mls/dL compared to 18.8 [IQR 17.4, 20.1]mls/dL, p,0.0001). Exercise tolerance
appeared unrelated to SaO2 but was significantly worse in patients with lower oxygen content (p,0.0001). A pre-defined
athletic group had higher Hb:SaO2 and serum iron:ferritin ratios than non-athletes with normal exercise capacity. PAVM
embolisation increased SaO2, but arterial oxygen content was precisely restored by a subsequent fall in haemoglobin: 86
(87.8%) patients reported no change in exercise tolerance at post-embolisation follow-up.
Significance: Haemoglobin and oxygen measurements in isolation do not indicate the more physiologically relevant
oxygen content per unit blood volume. This can be maintained for SaO2 $78.5%, and resets to the same arterial oxygen
content after correction of hypoxaemia. Serum iron concentrations, not ferritin, seem to predict more successful
polycythaemic responses.
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Introduction
The primary function of haemoglobin is to transport oxygen
from the alveolar capillaries to the tissues. Blood oxygen content is
determined by the haemoglobin concentration, and the partial
pressure of oxygen in blood (PaO2) which governs the percentage
haemoglobin saturation (SaO2) [1]. In turn, the overall transport
of oxygen to the tissues depends upon the oxygen content of
arterial blood, and the volume of blood reaching the tissues in any
given period (cardiac output) [1]. Profound arterial hypoxaemia
can be tolerated if subjects are gradually acclimatised [2][3][4][5].
Mechanisms that help sustain oxygen delivery include higher
haemoglobin concentrations through secondary erythrocytosis/
polycythaemia [2][3][4], and tissue changes that optimise energy
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metabolism including suppression of mitochondrial biogenesis and
oxidative metabolism[5]. Similarly, severe anaemia is tolerated if
chronic compensatory mechanisms can be employed: anaemic
patients unable to sustain normal haemoglobin concentrations
have hyperdynamic circulations, with high cardiac outputs
accompanied by lower systemic vascular resistance [6][7][8].
Although this is an integrated system of oxygen delivery, and
challenged by multiple different pathological states, the problem is
that components are generally discussed in a discipline-restricted
manner. Oxygen and clinical practice guidelines are based on
PaO2 and/or SaO2 measurements: of more than 2,700 PubMed
results retrieved using ‘‘oxygen’’ and ‘‘guidelines,’’ only 106 were
found by including the term ‘‘haemoglobin’’ [or ’’hemoglobin’’],
with relevant articles predominantly restricted to the anaesthetic/
critical care literature. Synthesis of iron-containing haemoglobin is
impaired by iron deficiency which affects more than a billion
individuals worldwide[9], but in the iron deficiency literature,
anaemia is generally discussed without reference to oxygen
transport: On 25.11.2013 although there were 14,284 PubMed
references for ‘‘iron’’, ‘‘deficiency’’ and ‘‘anaemia/anemia,’’ only
73 were retrieved including the terms ‘‘oxygen’’ and either
‘‘delivery’’ or ‘‘transport.’’ In addition, it is rarely discussed that
hypoxaemia caused by low inspired oxygen concentrations, at
altitude [2][3][4][5], or due to alveolar/airways disease [10], is
inevitably accompanied by a separate process, namely hypoxic
pulmonary vasoconstriction (HPV) [2][11]. HPV is the physio-
logical response to alveolar hypoxia, responsible for ventilation-
perfusion matching [2][11]. As HPV leads to local or generalised
elevation of pulmonary vascular resistance [2][11], this process has
the potential to confound physiological and clinical responses in
hypoxaemic subjects.
Hypoxaemic patients with pulmonary arteriovenous malforma-
tions (PAVMs) [12] provide an opportunity to study integrated
oxygen/haemoglobin relationships without confounding hypoxic
pulmonary vasoreactivity: PAVMs are abnormal blood vessels that
usually develop by teenage years, and provide direct capillary-free
communications between the pulmonary and systemic circulations
[12]. Hypoxaemia results from deoxygenated pulmonary arterial
blood transiting these right-to-left (R-L) shunts and bypassing the
alveolar capillary sites of gas exchange. There is good agreement
between the calculated R–L shunt using measured SaO2, and the
anatomic R-L shunt, confirming that the R-L shunt is the
predominant cause of the arterial hypoxaemia [13]. Hypoxaemic
PAVM patients are therefore not at risk of hypoxic pulmonary
hypertension, and pulmonary vascular resistance at rest is low in
patients with severe PAVMs [14][15]. Arterial PaO2 and SaO2 are
inversely related to the proportion of the cardiac output passing
through the R–L shunts [13][14][15][16][17][18][19][20][21]
[22][23][24], and hypoxaemia may be severe. As at altitude, and
in patients with other cardiorespiratory cyanotic disease, second-
ary polycythaemia [13][14][15][16][17][18][19][20][21][22][23]
[24][25] and increased cardiac outputs [14][19] help to sustain
long term oxygen delivery in hypoxaemic PAVM patients.
PAVM patients provide a particularly good model in which to
study integrated oxygen/haemoglobin relationships not only
because of the absence of HPV, but also because serial evaluations
can be performed before and after correction of hypoxaemia by
PAVM embolisation treatments which are recommended to
prevent paradoxical embolic strokes and other complications
[23][24][25][26][27]. High proportions of PAVM patients have
iron deficiency, due to the presence of underlying hereditary
haemorrhagic telangiectasia (HHT), [28][29], and inadequate
replacement of haemorrhagic iron losses [30][31][32]. Important-
ly, such iron deficiency generally occurs in the absence of
confounding inflammation: inflammatory markers such as C
reactive protein are generally normal [24][33], and hepcidin
concentrations are appropriate for iron stores, exhibiting the same
relationships with ferritin as in the general population [30].
Our aim was to evaluate oxygen/haemoglobin relationships in a
large cohort of PAVM patients before and after embolisation
treatment, and in the presence and absence of iron-restricted
erythropoesis, in order to obtain insights not available from other
hypoxaemic pathologies or models. This is important for PAVM
patients because they are currently managed by oxygen/polycy-
thaemia guidelines extrapolated from evidence in other patient
groups [34][35][36], and our clinical observations suggested that
the extrapolated guidelines were not serving the population well
[12][37].
The study objectives were achieved. Here we present data that
provide new insights into the regulation of blood oxygen content
through polycythaemia, and add to the evidence base from which
clinical guidance may be developed.
Methods
Ethical approved was from the Hammersmith, Queen Char-
lotte’s, Chelsea, and Acton Hospital Research Ethics Committee
(LREC 2000/5764: ‘‘ Case Notes Review: Hammersmith Hospital
patients with pulmonary arteriovenous malformations and hered-
itary haemorrhagic telangiectasia (HHT).’’) The ethics committee
approved the review of the case notes for research purposes
without seeking individual consents. Individuals were asked for
written consent as part of separate ethics approvals for any
research protocol (questionnaire, blood test, scan or other study)
that was not part of standard clinical practice, but no such data are
reported in this manuscript.
Table 1. Demographics of 165 consecutive unselected PAVM
patients.
Continuous variables N Range Median IQR
Age (yr) 165 17–87 49 36?5, 62?5
SaO2 at presentation (%){ 165 78?5–99 95 92, 96
Pulse at presentation (min21) { 164 58?5–123 88 78?8, 98?5
Haemoglobin (g/dl) 160 7?7–20?9 14?1 12?8, 15?6
Haematocrit (%) 159 0?26–0?61 0?43 0?40, 0?46
Red blood cell (RBC) count 159 2?87–7?65 4?9 4?6, 5?2
MCH, pg/cell 159 16?5–35?4 29?8 28, 31?3
MCHC, g/dl 159 26?6–36?7 33?5 32?2, 34?3
MCV, fl 160 62?1–104 88?4 85?5,92?6
Serum iron (mmol/l)D 141 1–55 14 9, 19?5
Transferrin saturation index (TfSI%)D 138 0–71 24 15, 32
Ferritin (mg/L) 105 3–409 34 19?5, 68?5
Demographics of the 165 PAVM Patients. N, number of datasets: values
,165 imply that data was not available for a subgroup of patients. {SaO2
measured continuously at rest for 10 minutes standing breathing room air, with
recordings at one minute intervals, and reported values the mean of the
readings after 7, 8, 9 and 10 minutes. MCH, mean corpuscular haemoglobin.
MCHC, mean corpuscular haemoglobin concentration. MCV, mean corpuscular
volume. D Blood test timings were standardised to catch the afternoon peak in
iron levels as described in the online supplement to Livesey et al. [33].
doi:10.1371/journal.pone.0090777.t001
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Clinical evaluations
Due to the pan-UK referral base to our PAVM/HHT service,
patients are initially evaluated in single day assessments (see www.
imperial.ac.uk/nhli/hht_pavm_patient). For patients referred with
suspected/confirmed HHT [38][39], PAVM screening or assess-
ment is performed using validated SaO2 measurements [24], and
thoracic CT scans if not performed previously/recently. The study
cohort represents the 165 consecutive patients with CT-proven
PAVMs first seen between June 2005- September 2010, and
excludes the May 1999-May 2005 patients whose findings [23]
precipitated the current study.
Presentation assessments. At initial assessment, SaO2 was
measured by pulse oximetry (Ohmeda Biox 3900, Boulder,
Colorado) while breathing room air. Measurements were made
for 10 minutes in the erect posture, recorded at one minute
intervals, with the mean value from minutes 7–10 reported, as
utilised in previous clinical studies [17][20][21][23][24][33][40]
and recently validated [24]. To minimise diurnal variability for
iron measurements, timings of blood tests were standardised to
mid-late afternoon [33]. Full blood counts measured haemoglobin,
haematocrit, red blood cell (RBC, erythrocyte) number, mean
corpuscular haemoglobin (MCH), mean corpuscular haemoglobin
Figure 1. Basis of polycythaemia and anaemia responses in PAVM patients. Univariate associations demonstrating individual patient data
(small diamonds), linear regression lines, and 95% confidence intervals (shaded) for two way relationships. A–C): The polycythaemic response to
hypoxaemia. A) Lower SaO2 was associated with higher haemoglobin (the ‘polycythaemic response’). B) This polycythaemia was not attributable to
increased haemoglobin concentration in red cells (mean corpuscular haemoglobin concentration, MCHC). C) Instead, the polycythaemia reflected
increased red cell number (RBC), that is, secondary erythrocytosis, D–F) The anaemic response to iron deficiency: D) Lower serum iron concentrations
were associated with lower haemoglobin (the ‘anaemic response’). E) This anaemic response to iron deficiency resulted from reduced haemoglobin
concentration in red cells (MCHC), and not a change in red cell number (RBC) (F).
doi:10.1371/journal.pone.0090777.g001
PAVMs and Iron Deficiency
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concentration (MCHC) and red cell distribution width (RDW)) on
XE Series Analysers (Sysmex, UK). Biochemical indices including
serum iron, transferrin saturation index (TfSI) and ferritin were
measured on Ci1600 Architect Analysers (Abbott Diagnostics,
Ireland).
Embolisation admissions and follow up. Embolisation
was performed as described elsewhere [12][37][40][41] in 98
patients during standardised 48hr admissions. Pulmonary artery
pressures (PAP) were recorded by a centrally-placed catheter prior
to contrast injection [12][37][40][41]. Embolisation was not
indicated in 66 patients, primarily due to PAVMs with feeding
arteries too small for treatment (n = 63 including two who had
previous maximal treatment elsewhere). Three patients had
contraindications [40][42], including two with very severe
pulmonary hypertension, one of whom was on a liver transplant
waiting list. One patient declined embolisation. Twenty patients
required more than one planned embolisation session to achieve
maximal embolisation; seventeen required two sessions which
spanned 1.5–13 (median 4.3) months; three required three sessions
spanning 19–24 (median 20) months. Oximetry and blood tests
were repeated in the 24hs before each pulmonary angiography/
embolisation session, and oximetry the day after embolisation.
Oximetry and blood tests were repeated in a standardised follow-
up clinic which took place at least 2 months after the final
embolisation. In their first post-embolisation follow up clinic,
treated patients were asked in a non biased manner whether they
had noticed any differences after embolisation, then asked to
report what those differences were.
Study methodology
Pre-study power calculations to determine series length were
performed on the HHT thrombotic endpoints under parallel study
[23][24][33][43]. Blinded to all other measurements (and subse-
quent analyses), two investigators (VS, CLS) assigned patient’s
clinic reports of their presentation exercise capacity to a scale [44]
adapted from the Medical Research Council dyspnoea scale [45].
Because many were highly athletic individuals, the ‘‘normal’’
Grade 1 classification was subclassified into Grade 1a (if
participating in intense sporting activity such as rowing, football,
distance cycling or gym activities at least three times per week),
and Grade 1b (representing other normals, who described
dyspnoea only on strenuous exertion). Grades 2–5 describe
progressively lower exercise tolerance/greater dyspnoea. The
grading of individuals in the current cohort was published in
Abstract format in 2011 [44]. Treated patients were also stratified
as ‘‘improved exercise tolerance’’ or ‘‘no improvement’’ by their
reports of changes post embolisation, blinded to other patient
Figure 2. Three-way plots of relationships between haematinic indices and SaO2. Three-way plots of relationships between SaO2 (y axis),
ferritin/iron (x axis), and haematinic index (z axis). The most hypoxaemic patients are at the bottom of each graph, and patients with the lowest
ferritin/iron levels to the left. The z axis effectively provides a 3 dimensional plot in which contours range from blue (lowest value of modelled
haematinic variable) to red (highest values). A–D) Serum ferritin/SaO2 stratifications for the 105 PAVM patients with serum ferritin measurements: A)
SaO2/ferritin/haemoglobin. B) SaO2/ferritin/haematocrit. C) SaO2/ferritin/MCHC. D) SaO2/ferritin/red cell count. Note that higher haemoglobin,
haematocrit and MCHC are seen across the normal range for ferritin (10–150 or 20–300 mg/L, according to gender), but higher RBC number is only
seen in patients with low or subnormal ferritin. E–H) Serum iron/SaO2 stratifications for the 141 PAVM patients with serum iron measurements. E)
SaO2/iron/haemoglobin. F) SaO2/iron/haematocrit. G) SaO2/iron/MCHC. D) SaO2/iron/red cell count. Although serum iron and serum ferritin were
correlated (Spearman rho 0.34, p = 0.006), serum iron did not show the same relationships with hematinic indices as serum ferritin (contrast A and E; B
and F; C and G; D and H). The highest haematinic indices were observed with serum iron above the normal range (7–27 mmol/L).
doi:10.1371/journal.pone.0090777.g002
Figure 3. Arterial oxygen content stratified by oxygen saturation (SaO2). Oxygen content across all degrees of hypoxaemia, calculated by
SaO2 x haemoglobin x 1.34/100, where SaO2 was expressed as a %, and 1.34mls is the amount of oxygen carried per gram of haemoglobin.[1] The bold
black line represents the regression line for all patients, irrespective of iron status (p = 0.69). Grey diamonds/dotted line/shaded 95% confidence
interval represent patients without iron deficiency (p = 0.33). Red diamonds/dotted line/shaded 95% confidence interval represent patients with iron
deficiency (p = 0.97).
doi:10.1371/journal.pone.0090777.g003
PAVMs and Iron Deficiency
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variables. Study follow up continued until all feasible first post
embolisation assessments had been performed. In order to avoid
inadvertent introduction of bias, other than entering data for
remaining post embolisation assessments, no additional informa-
tion was sought, no additional assessments were performed for the
purposes of this study, and specifically, groupings generated by
exercise tolerance or subsequent statistical analyses were not
restudied or reassessed.
For the current study, oxygen content of blood and iron
deficiency were generated as new variables by command line
entry, blinded to all other parameters. Arterial oxygen content was
calculated by SaO2 x haemoglobin x 1.34/100 where SaO2 was
expressed as a %, and 1.34mls is the amount of oxygen carried per
gram of haemoglobin [1]. Iron deficiency was assigned as absent
(‘‘0’’) if ferritin, iron and TfSI were all clearly in the normal range
(ferritin.20 mg/L, serum iron.11 mmol/L and TfSI.20%). In
keeping with current recommendations [46][47][48], iron defi-
ciency was assigned as present (‘‘1’’) if same-day ferritin was
,15 mg/L. As discussed previously by ourselves [24][33] and
others [46][47][48], ferritin may be spuriously high in iron
deficiency due to concurrent pathologies. Thus following haema-
tinic validations [24], iron deficiency was also assigned as present
(‘‘1’’) for individuals with both iron and TfSI clearly subnormal
Figure 4. 165 PAVM patients graded according to self-reported exercise tolerance. A) SaO2 relationships. Error bars represent mean and
standard deviation. Similar trends were observed for median and IQR (data not shown). B) Oxygen content, calculated by SaO2 x haemoglobin x 1.34/
100, where SaO2 was expressed as a %, and 1.34mls is the amount of oxygen carried per gram of haemoglobin [1]. Error bars represent mean and
standard deviation, but a similar trend was observed for median and IQR (data not shown).
doi:10.1371/journal.pone.0090777.g004
Figure 5. Boxplot comparisons of athletes and other individuals with normal exercise tolerance. Individuals with normal exercise
tolerance (Grade 1) were subclassified into Grade 1a (athletes, grey symbols/lines, if participating in intense sporting activity such as rowing, football,
distance cycling or gym activities at least three times per week), and Grade 1b (other normals, red symbols/lines, if they described dyspnoea only on
strenuous exertion). All assignments were made blinded to physiological parameters [44]. A) Haemoglobin (Hb) adjusted for SaO2, presented as
(100*haemoglobin)/SaO2. Mann Whitney p value = 0.0059. P values were also calculated by Kruskal Wallis across all exercise grades, when Dunn’s
post test correction comparing the athletic and non athletic normals gave a p value of,0.05. B) Serum iron. Mann Whitney p value = 0.010. P values
were also calculated by Kruskal Wallis across all exercise grades, when Dunn’s post test correction comparing the athletic and non athletic normals
gave a p value of,0.05.
doi:10.1371/journal.pone.0090777.g005
PAVMs and Iron Deficiency
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(,7 mmol/L and ,20% respectively). All other combinations
were assigned as intermediate/unknown (‘‘.’’).
Statistical Analyses
STATA IC version 12 (Statacorp, Texas) and GraphPad Prism
5 (Graph Pad Software Inc, San Diego) were used to calculate
distributions of participant-specific variables, to perform compar-
isons between groups, and to generate graphs. Two group
comparisons were by Spearman rank or Mann Whitney; three
group repeated measures comparisons by Kruskal Wallis with
post-test Dunns corrections. Univariate and multivariate linear,
logistic and quantile regression was performed in STATA IC
version 12 (Statacorp, Texas).
Results
Series demographics
The 165 patients were aged 17–87 (median 49) years. Sixty-two
(37.6%) were male. 159 (96.4%) patients had underlying
hereditary haemorrhagic telangiectasia (HHT) [38]. PAVMs had
been diagnosed by a variety of routes, most commonly screening
for PAVMs in suspected HHT patients/families (N= 62 [37%]);
incidental detection by chest x-rays or thoracic/abdominal CT
scans (N= 34 [20.5%]); investigations following strokes, brain
abscess or neurological symptoms (N= 18 [12%]); and PAVM
respiratory symptoms (N= 17 [10%]). Only 15 (9.1%) patients had
evidence of significant co-existing disease, with obstructive
spirometry due to either asthma or COPD the most common.
One patient was receiving supplementary oxygen therapy at
presentation and in follow up. No patients underwent venesection
in the course of these studies.
SaO2 at rest ranged from 78.5–99% (median 95%, Table 1). In
keeping with the high prevalence of HHT, many of the PAVM
population had biochemical and haematinic evidence of iron
deficiency (Table 1). Overall, haemoglobin ranged from 7.7 to
20.9 g/dl (median 14.1 g/dl), haematocrit from 0.26 to 0.61
(median 0.43).
Basis of polycythaemia and anaemia responses
As expected, haemoglobin values were higher in patients with
lower SaO2 (Figure 1A). On average, for every 1% fall in SaO2,
haemoglobin rose by 0.82 g/dl (regression coefficient -0.82 (95%
CI 21.12, 20.51, p,0.0001). There was no change in the
haemoglobin concentration per red cell (Figure 1B), and the rise in
haemoglobin reflected higher red cell counts at lower SaO2
(Figure 1C). In the same population, lower serum iron was
associated with lower haemoglobin (Figure 1D), attributable to a
reduced haemoglobin concentration per red cell, with no change
in red cell count (Figure 1E, 1F).
To portray the inter-relationships graphically, three-way con-
tour plots were generated. These indicated that the polycythaemic
response was evident even in the setting of low ferritin
concentrations: For haemoglobin (Figure 2A), haematocrit
(Figure 2B), and MCHC (Figure 2C), higher values were observed
in more hypoxaemic patients across all ferritin values. The
erythrocytotic response in hypoxaemic patients was particularly
prominent in patients with subnormal serum ferritin (Figure 2D).
Figure 6. Blood oxygen content pre and post embolisation.
Post embolisation data were obtained at clinic follow up at a median of
7 months (range (2–24) months after the final embolisation. Shaded
areas represent 95% confidence interval for quadratic regression line for
all 52 patients with pre and post embolisation haemoglobin
measurements (pseudo r2 0.44, p,0.0001). Open diamonds represent
individuals with pre embolisation serum iron ,4 mmol/L.
doi:10.1371/journal.pone.0090777.g006
Table 2. Changes in SaO2, haemoglobin, and oxygen content following PAVM embolisation.
Pre (day -1 or 0) Immediate post (day 1)
Late follow up (Late
post) Comparison p values
Median IQR Median IQR Median IQR Pre to day 1
Day 1 to late
post
Pre to late
post
SaO2 (%, N= 71) 94.0 91.8, 95.8 96.3 95.3, 97.0 96.0 95.0, 97.0 ,0.001 ns ,0.001
Haemoglobin (g/dl,
N = 51)
14.9 13.3, 16.1 . . 14.3 13.3, 15.2 . . 0.17
Oxygen content (ml/dl,
N = 51)
18.3 16.9, 20.1 19.4 17.4, 20.9 18.4 16.9, 19.3 ,0.001 ,0.001 ns
Data are provided only where available at all comparative timepoints for stated variable: immediately pre embolisation (previous evening, or same morning); the
morning following embolisation (‘‘immediate post (day 1)’’); and at late follow up (‘‘late post’’), which referred to the first post embolisation follow up clinic, 2–24
(median 7) months post final embolisation. Where several embolisations took place in a series (17 patients required two sessions and 3 required three sessions), data are
only reported pre and post final embolisation. The day 1 arterial oxygen content was calculated using the day 1 SaO2 and pre-embolisation haemoglobin. P values for
three way comparisons were calculated by Friedman, except for two way pre post haemoglobin comparisons which were calculated by Mann Whitney. IQR, interquartile
range. ns, non significant (exact figure not provided from Kruskal Walllis.)
doi:10.1371/journal.pone.0090777.t002
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Different haematinic/SaO2 inter-relationships were observed
with serum iron. Three-way contour plots indicated that for
patients with lower SaO2, polycythaemic responses (higher
haemoglobin (Figure 2E), higher haematocrit (Figure 2F), higher
MCHC (Figure 2G) and higher red cell count (Figure 2H)) were
evident only in the setting of high-normal serum iron concentra-
tions.
Preservation of arterial oxygen content by polycythaemic
response
Due to the higher haemoglobin in more hypoxaemic patients,
oxygen content per unit blood volume was similar across all
degrees of hypoxaemia (bold black line, Figure 3). SaO2 explained
only 0.1% of the variance in arterial oxygen content per unit blood
volume (p = 0.83). In non iron deficient patients, the median
arterial oxygen content was 18.8 [IQR 17.4, 20.1]ml/dl. Iron
deficient patients had similar SaO2 to non iron deficient patients,
but haemoglobin was ,2 g/dl lower. As a result, arterial oxygen
content in iron deficient patients either defined conventionally by
ferritin ,15 mg/L (median 16.0 [IQR 14.9, 17.4]ml/dl) or by
‘‘low iron state’’ which included patients with serum iron
,11 mmol/L irrespective of ferritin (median 16.3 [IQR 14.8,
18.1]ml/dl), were both substantially lower than in non iron
deficient patients (p values,0.0001, Figure 3).
Consequences of reduced oxygen content
The median values for arterial oxygen content (18.8 ml/dl
versus 16.0 ml/dl, see Figure 3) imply that per unit blood volume,
oxygen content was reduced by approximately 15% in the iron
deficient group. Graded self-reported exercise tolerance [44] was
used as a crude indicator of whether compensating for reduced
blood oxygen content was achievable.
Figure 4A demonstrates that there was no clear relationship
between SaO2 (the most commonly measured index of oxygen-
ation in clinical practice [34][35],) and graded exercise tolerance:
Seven individuals regularly participated in intense sporting activity
despite marked resting hypoxaemia (SaO2,90%, Figure 1). In
contrast there was a very clear inverse correlation between exercise
grade and arterial oxygen content, which incorporates both SaO2
and haemoglobin. As shown in Figure 4B, exercise tolerance was
worse in patients with lower oxygen content (coefficient 20.0012,
p,0.0001), with the trend evident across all grades of exercise
tolerance.
Oxygen content and iron relationships in athletes
Figure 4B suggested that the blood oxygen content may be
higher in the pre-defined athletic group than the other Grade 1
normals. Haemoglobin tended to be higher for the degree of
hypoxaemia in the athletes, compared to non-athletic normals
(Figure 5A). This could not be ascribed to differential use of iron
tablets: excluding the 25 iron tablet users (6 athletes, 19 non
athletic normals) the higher ratio of [100*haemoglobin]/SaO2 in
the athletic group persisted (median 16.6 [IQR 14.7, 20.0] vs 15.2
[IQR 12.2, 17.7], p = 0.016). This would be in keeping with the
limited evidence suggesting that exercise training can increase total
haemoglobin and red cell mass, attributed to stimulated bone
marrow erythropoiesis [49].
Table 3. Demographics, and univariate associations with improvement in exercise capacity post embolisation for the 98 PAVM
patients.
No reported improvement Improved exercise tolerance p value*
Binary variables Total N % Total N %
Gender (N and % female) 86 52 60.0 12 7 58.3 0.90
Ever smoked 76 35 46.1 11 12 27.3 0.25
Continuous variables Total Median IQR Total Median IQR
Age (yr) 86 48 38, 60 12 49.8 39.5, 60.5 0.71
Body mass index (BMI) 78 26.4 22.6, 29.0 12 25.4 22.5, 32.5 0.51
SaO2 (%) 86 93.6 90.8, 95.5 12 90.1 81.1, 94.5 0.12
Haemoglobin (g/dl) 84 14.9 13.4, 16.1 12 13.7 12.4, 16.3 0.38
Arterial oxygen content (ml/dl) 84 18.3 17.0, 20.1 12 16.4 15.3, 20.0 0.07
Mean corpuscular volume (MCV, fl) 84 88.8 85.5, 91.8 12 88.7 85.3, 94.8 0.92
Serum iron (mmol/l) 74 14.5 9,19 10 15 10, 20 0.79
Transferrin saturation index (%) 74 23 15,31 10 22 6, 35 0.59
Ferritin (mg/L) 45 30 21,67 8 28 11,67 0.76
Albumin (g/L) 72 41.5 39, 44 12 38 36,40.5 0.0086
PAP (systolic) 68 23 20,26 10 26 23,33 0.031
PAP (diastolic) 68 8 7,10 10 9 7,13 0.024
PAP (mean) 68 14 12,16.5 10 16 14,21 0.037
Change in SaO2 post embolisation (%) 98 2.38 0.75,5.0 12 4.25 1.375, 7.25 0.54
Change in oxygen content post emb.(ml/dl) 44 20.2 21.0, 0.41 9 0.51 20.08, 1.11 0.14
Patients stratified into those reporting and not reporting improved exercise tolerance. N, number with stated variable; IQR, interquartile range. PAP, pulmonary artery
pressure; emb., embolisation. *P values calculated by logistic regression, and shown in bold where ,0.05: Key odds ratios (and 95% confidence intervals) were 0.71
(0.56, 0.92) for albumin; 1.12 (1.01, 1.24) for PAP(systolic); 1.31 (1.04, 1.65) for PAP (diastolic); and 1.18 (1.01, 1.40) for PAP (mean). Note inverse associations are indicated
by odds ratios ,1.
doi:10.1371/journal.pone.0090777.t003
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The current study cohort suggests a potentially relevant change
in iron handling: While there was no difference in serum ferritin
values between the athletes (median 38 [IQR 19, 77]mg/L) and
non-athletic normals (median 38 [IQR 16, 73]mg/L), the athletic
group had higher serum iron concentrations (median 19.5 [IQR
13,28]mmol/l compared to 14 [IQR 9,17]mmol/l, p = 0.01
(Figure 5B)). Again, this could not be ascribed to differential use
of iron tablets: excluding the 25 iron tablet users, median serum
ferritin values in athletes and other normals were very similar at
43.5 [IQR 19, 86]mg/L and 40 [IQR 25, 78]mg/L respectively.
However the differences in serum iron concentrations persisted
(athletes: median 21 [IQR 13, 28]mmol/l; non athletic normals: 14
[IQR 10,18]mmol/l, p = 0.043).
Effect of embolisation and correction of hypoxaemia
In the 98 patients whose PAVMs were treated by embolisation,
SaO2 improved immediately (median increase +2.5% (IQR +0.75,
+5.0%, Table 2). Improvements were sustained on long term
follow up 2–24 (median 7) months later (Table 2). Haemoglobin
and haematocrit fell in the follow up period: for haemoglobin, the
value at a median of 7 months after final embolisation was 0.60 g/
dl lower (IQR21.3 g/dl, +0.1 g/dl) than at presentation (Table 2).
As a result, oxygen content in mls/dl generally returned to pre-
embolisation values (Table 2, Figure 6).
In these 98 patients, 86 (87.8%) reported no change in exercise
tolerance at their first post-embolisation follow up clinic at a
median of 7 months (range 2–24, [IQR 6, 9]) post final
embolisation. A common comment was feeling better initially
after embolisation, then returning to normal and the individuals
not being sure if this was because they had ‘got worse’ again, or
become more used to an improved state. We interpreted this as
reflecting an interim increase in arterial oxygen content before the
fall in haemoglobin documented in Table 2.
Twelve patients (12.2%) did report sustained improvements in
exercise tolerance, particularly on stairs, on hills, or during specific
sports. Three commented on an improved breathing pattern
during swimming (n= 2) or yoga (n= 1). Using logistic regression,
there was a trend for improvement in exercise tolerance to be
reported more commonly by patients with lower oxygen content at
presentation, but no relationship with degree of improvement in
oxygen content post embolisation. Improved exercise tolerance
was reported more commonly by patients with lower serum
albumin, which is a marker of illness/inflammation (attributed to
reduced hepatic synthesis, increased albumin catabolism and
vascular permeability [50]). An improvement in exercise tolerance
was also reported more commonly by patients with higher PAP
(Table 3), especially PAP(diastolic) which most closely reflects
pulmonary vascular resistance [51]. We concluded that co-existing
diseases were associated with less successful compensation to initial
hypoxaemia, and improved exercise tolerance post embolisation.
Discussion
In this study, which examines chronic compensatory changes in
an unselected cohort of 165 consecutive patients with PAVMs, we
demonstrate that the adaptive polycythaemic/secondary erythro-
cytotic response not only maintains arterial oxygen content for
SaO2 $78?5%, but also resets to the same arterial oxygen content
after correction of hypoxaemia. Impairment of haemoglobin
synthesis due to iron deficiency was the key determinant of
reduced oxygen content, and reflected the high proportion of
PAVM patients who had underlying HHT. Serum iron concen-
trations rather than ferritin were more predictive of a successful
polycythaemic response. Future studies will be required to test if
higher serum iron:ferritin ratios are a consequence of athletic
training [49][52], or prerequisite. The preliminary data on
improved exercise tolerance following embolisation treatment of
PAVMs suggest factors unrelated to iron deficiency are also
important in preventing optimal compensations to hypoxaemia.
Strengths of the current study include the large number of
patients studied with consistent methodologies, the extremely
reduced SaO2 present long term, the general absence of
confounding hypoxic pulmonary vasoreactivity and inflammation,
and the high proportion with significant iron deficiency. The
absence of arterial blood gas measurements of PaO2 may be
considered a weakness, but the reproducibility of the replicate
pulse oximetry SaO2 measurements [24] render this criticism less
important. Not all patients had ferritin measured, but in view of
the similar cohorts identified by low serum iron and the ferritin
values conventionally used to define iron deficiency
[24][46][47][48], we concluded that for the parameters under
examination, it was appropriate to use serum iron ,11 mmol/L as
a marker of an iron insufficient state. Although a single centre
study, there was little bias introduced by geography (UK-wide
referrals), or type of presentation.
The current data are important for oxygen/polycythaemia
guidance for PAVM patients, currently extrapolated from data in
other patient groups, particularly patients with COPD where HPV
also operates. The guidelines [34][35][36] are interpreted as
stating that PAVM patients who are hypoxaemic and polycythae-
mic should have venesection (to reduce plasma viscosity [36]), and
oxygen supplementation [34][35][36]. For HHT/PAVM patients,
it is not high haematocrit/haemoglobin that is associated with
venous thromboembolism (VTE) [33][43], but markers of iron
deficiency [33] which would be exacerbated by venesection
[36][53][54]. Venesection will inevitably result in rebound
polycythaemia unless iron deficiency is induced [53][54]. Supple-
mentary oxygen is generally prescribed to hypoxaemic patients
acutely to reduce risks of hypoxic tissue injury [34][35], and longer
term to reduce the risks of developing hypoxic pulmonary
hypertension [11][34][35] and/or hyperviscosity states [36]. The
current study reminds of the normal long-term compensations that
help prevent tissue hypoxia. Additionally, multiple studies
demonstrate that low SaO2/PaO2 are tolerated well by PAVM
patients at rest [13][14][15][16][17][19][20][22][24][25][26], on
exercise [14][15][18][19], and even in flight when barometric
pressure and alveolar oxygen tension fall further [55]. The data in
the current manuscript suggest the PAVM patients most likely to
benefit from oxygen supplementation would be iron deficient
patients with less successful polycythaemic compensatory respons-
es, and this could be tested in future trials.
Taken more broadly, the data reemphasise the importance of
combining haemoglobin and SaO2 to evaluate the oxygen content
of arterial blood. Using a term such as OaHb for arterial oxygen
content per unit volume on air, calculated by SaO2 x haemoglobin x
1.34/100, may serve as an aide memoire. The haemodynamic
implications of impaired haemoglobin synthesis are not currently
emphasised, most likely attributable to the discrepancy identified
by He´bert et al [8], between the copious data in the old
physiological literature (summarised in [7]) and paucity in more
recent clinical studies. In the current study, average arterial
oxygen content was 15% lower in the iron deficient group,
implying that unless there were local tissue compensations, cardiac
output would need to be approximately 15% higher to deliver the
same amount of oxygen to the tissues [1][7]. The incremental
increase would be greater in higher output states, for example on
exercise, during sepsis, or for HHT patients with hepatic and/or
other visceral AVMs with left-to-right shunting. The crude
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exercise data presented here suggest limitations in cardiac/
circulatory compensatory capacity in the setting of lower blood
oxygen content, but this will clearly need to be addressed in
targeted prospective studies.
In conclusion, discipline-restricted discussions of haemoglobin
or commonly measured oxygen parameters in isolation do not
address the more physiologically relevant arterial oxygen content
(mls of oxygen per unit blood volume). For hypoxaemic patients,
secondary erythrocytosis maintains the oxygen content of blood,
provided the bone marrow has sufficient time, function, and iron
to respond, and this may be enhanced by athletic training.
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